4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...

SAN FRANCISCO (Reuters) - Vector Capital said on Wednesday it raised a $1.4 billion private equity fund, giving the U.S. buyout firm more firepower to pursue acquisitions in the technology sector as ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Forward-looking: Recent big game releases appear to confirm that ray tracing and path tracing are the future of graphics rendering. However, these techniques remain prohibitively computationally ...